|
1
|
Northcott PA, Robinson GW, Kratz CP,
Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW,
Malkin D, Taylor MD, et al: Medulloblastoma. Nat Rev Dis Primers.
5:112019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ris MD, Walsh K, Wallace D, Armstrong FD,
Holmes E, Gajjar A, Zhou T and Packer RJ: Intellectual and academic
outcome following two chemotherapy regimens and radiotherapy for
average-risk medulloblastoma: COG A9961. Pediatr Blood Cancer.
60:1350–1357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moxon-Emre I, Bouffet E, Taylor MD,
Laperriere N, Scantlebury N, Law N, Spiegler BJ, Malkin D, Janzen L
and Mabbott D: Impact of craniospinal dose, boost volume, and
neurologic complications on intellectual outcome in patients with
medulloblastoma. J Clin Oncol. 32:1760–1768. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Polkinghorn WR and Tarbell NJ:
Medulloblastoma: Tumorigenesis, current clinical paradigm, and
efforts to improve risk stratification. Nat Clin Pract Oncol.
4:295–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saha A, Salley CG, Saigal P, Rolnitzky L,
Goldberg J, Scott S, Olshefski R, Hukin J, Sands SA, Finlay J and
Gardner SL: Late effects in survivors of childhood CNS tumors
treated on Head Start I and II protocols. Pediatr Blood Cancer.
61:1644–1652; quiz 1653–1672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Garancher A, Ramaswamy V and
Wechsler-Reya RJ: Medulloblastoma: From molecular subgroups to
molecular targeted therapies. Annu Rev Neurosci. 41:207–232. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu KW, Pajtler KW, Worst BC, Pfister SM
and Wechsler-Reya RJ: Molecular mechanisms and therapeutic targets
in pediatric brain tumors. Sci Signal. 10:2017. View Article : Google Scholar
|
|
8
|
Robinson GW, Witt H and Resnick A:
Exploiting laboratory insights to improve outcomes of pediatric
central nervous system tumors. Am Soc Clin Oncol Educ Book.
35:e540–e546. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tamayo P, Cho YJ, Tsherniak A, Greulich H,
Ambrogio L, Schouten-van Meeteren N, Zhou T, Buxton A, Kool M,
Meyerson M, et al: Predicting relapse in patients with
medulloblastoma by integrating evidence from clinical and genomic
features. J Clin Oncol. 29:1415–1423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
von Bueren AO, Kortmann RD, von Hoff K,
Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber
N, Warmuth-Metz M, et al: Treatment of children and adolescents
with metastatic medulloblastoma and prognostic relevance of
clinical and biologic parameters. J Clin Oncol. 34:4151–4160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moroishi T, Park HW, Qin B, Chen Q, Meng
Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D and Guan KL: A
YAP/TAZ-induced feedback mechanism regulates Hippo pathway
homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Totaro A, Panciera T and Piccolo S:
YAP/TAZ upstream signals and downstream responses. Nat Cell Biol.
20:888–899. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maugeri-Saccà M and De Maria R: The Hippo
pathway in normal development and cancer. Pharmacol Ther.
186:60–72. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murakami M, Nakagawa M, Olson EN and
Nakagawa O: A WW domain protein TAZ is a critical coactivator for
TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc
Natl Acad Sci USA. 102:18034–18039. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Palma T, D'Andrea B, Liguori GL,
Liguoro A, de Cristofaro T, Del Prete D, Pappalardo A, Mascia A and
Zannini M: TAZ is a coactivator for Pax8 and TTF-1, two
transcription factors involved in thyroid differentiation. Exp Cell
Res. 315:162–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Liu CY, Zha ZY, Zhao B, Yao J,
Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors
mediate the function of TAZ in cell growth and
epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Zhao H, Li Y, Xia D, Yang L, Ma Y
and Li H: The role of YAP/TAZ activity in cancer metabolic
reprogramming. Mol Cancer. 17:1342018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Du S, Lei T, Wang H, He X, Tong R
and Wang Y: Multifaceted regulation and functions of YAP/TAZ in
tumors (Review). Oncol Rep. 40:16–28. 2018.PubMed/NCBI
|
|
20
|
Choi W, Kim J, Park J, Lee DH, Hwang D,
Kim JH, Ashktorab H, Smoot D, Kim SY, Choi C, et al: YAP/TAZ
initiates gastric tumorigenesis via upregulation of MYC. Cancer
Res. 78:3306–3320. 2018.PubMed/NCBI
|
|
21
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cassia GSE, Alves C, Taranath A, López NS,
Oztekin O, Gonçalves FG and Patay Z: Childhood medulloblastoma
revisited. Top Magn Reson Imaging. 27:479–502. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rutkowski S, von Hoff K, Emser A, Zwiener
I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre
ML, Biassoni V, et al: Survival and prognostic factors of early
childhood medulloblastoma: An international meta-analysis. J Clin
Oncol. 28:4961–4968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ramaswamy V, Remke M, Bouffet E, Bailey S,
Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, et al:
Risk stratification of childhood medulloblastoma in the molecular
era: The current consensus. Acta Neuropathol. 131:821–831. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Low JA and de Sauvage FJ: Clinical
experience with Hedgehog pathway inhibitors. J Clin Oncol.
28:5321–5326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Northcott PA, Korshunov A, Witt H,
Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins
CE, French P, et al: Medulloblastoma comprises four distinct
molecular variants. J Clin Oncol. 29:1408–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kool M, Korshunov A, Remke M, Jones DT,
Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van
Meeteren A, van Vuurden D, et al: Molecular subgroups of
medulloblastoma: An international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3, and
Group 4 medulloblastomas. Acta Neuropathol. 123:473–484. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Łastowska M, Trubicka J, Niemira M,
Paczkowska-Abdulsalam M, Karkucińska-Więckowska A, Kaleta M,
Drogosiewicz M, Tarasińska M, Perek-Polnik M, Krętowski A, et al:
ALK expression is a novel marker for the WNT-activated type of
pediatric medulloblastoma and an indicator of good prognosis for
patients. Am J Surg Pathol. 41:781–787. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takei H, Bhattacharjee MB, Rivera A,
Dancer Y and Powell SZ: New immunohistochemical markers in the
evaluation of central nervous system tumors: A review of 7 selected
adult and pediatric brain tumors. Arch Pathol Lab Med. 131:234–241.
2007.PubMed/NCBI
|
|
30
|
Cho YJ, Tsherniak A, Tamayo P, Santagata
S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L,
Eberhart CG, et al: Integrative genomic analysis of medulloblastoma
identifies a molecular subgroup that drives poor clinical outcome.
J Clin Oncol. 29:1424–1430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mendrzyk F, Radlwimmer B, Joos S,
Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP,
Reifenberger G, et al: Genomic and protein expression profiling
identifies CDK6 as novel independent prognostic marker in
medulloblastoma. J Clin Oncol. 23:8853–8862. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun L, Chen F, Shi W, Qi L, Zhao Z and
Zhang J: Prognostic impact of TAZ and β-catenin expression in
adenocarcinoma of the esophagogastric junction. Diagn Pathol.
9:1252014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Z, Liu P, Zhou X, Wang T, Feng X, Sun
YP, Xiong Y, Yuan HX and Guan KL: Endothelin promotes colorectal
tumorigenesis by activating YAP/TAZ. Cancer Res. 77:2413–2423.
2017. View Article : Google Scholar : PubMed/NCBI
|
